Zogenix Rallies 7% On New Fintepla Data For Dravet Syndrome, , on October 16, 2020 at 7:53 am

Financial News
By
On October 16, 2020
In Financial News
Tags:

Shares in Zogenix (ZGNX) rallied 7% in Thursday’s after-hours trading after the company shared new data for Fintepla (fenfluramine) oral solution in Dravet syndrome at the Child Neurology Congress 2020.Dravet syndrome is a rare, highly refractory form of infant- and childhood-onset epilepsy marked by frequent and often prolonged seizures that are difficult to control with existing medications, significant cognitive and motor impairments, and a higher risk of sudden death.Efficacy was assessed as the reduction in monthly convulsive seizure frequency (MCSF) from core study baseline. Patients experienced a clinically meaningful and statistically significant reduction in MCSF over the entire treatment period of two years (-63%).“In addition to the significant convulsive seizure reductions seen in all three multi-national Phase 3 studies of FINTEPLA in Dravet syndrome, we are proud to collaborate with expert clinician investigators to show the durability of the clinically meaningful seizure reduction that FINTEPLA provided for patients treated for up to two years,” said Bradley S. Galer, Chief Medical Officer at Zogenix.Furthermore, new post-hoc data analysis demonstrated that for every two to three patients treated with Fintepla, one patient achieved ≥75% (profound) convulsive seizure reduction compared with placebo.“We believe these new data analyses further showcase the clinical value that FINTEPLA provides for many Dravet syndrome patients and their families” stated Galer.Shares in ZGNX have plunged over 60% year-to-date, but analysts have a cautiously optimistic Moderate Buy consensus on the stock’s outlook. That’s with an average analyst price target of $45- indicating shares can more than double from current levels.“We continue to believe in Fintepla’s long-term potential to be the standard of care for Dravet Syndrome, particularly following promising early launch indicators” comments Mizuho Securities analyst Difei Yang. She has a buy rating on Zogenix and $55 price target.She sees upside in ZGNX shares driven by Fintepla in Dravet, an area of high unmet medical need and from additional pipeline indications including Lennox–Gastaut syndrome; adding that the firm’s revenue estimates of $4.2mil/$45.7mil for 2020/2021 are achievable with potential upside. (See Zogenix stock analysis on TipRanks)Related News: Vertex Sinks 12% On Halt of VX-814 Development; Merrill Lynch Says Buy J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa More recent articles from Smarter Analyst: * Intuitive Surgical Plunges 4% Despite 3Q Earnings Beat * Cars.com Soars 26% On Strong 3Q Sales Outlook, Analyst Upgrade * Marten Transport Sinks 8% After-Hours On 3Q Revenue Miss * Raytheon Scores $239M US Air Force Contract Modification,

Zogenix Rallies 7% On New Fintepla Data For Dravet SyndromeShares in Zogenix (ZGNX) rallied 7% in Thursday’s after-hours trading after the company shared new data for Fintepla (fenfluramine) oral solution in Dravet syndrome at the Child Neurology Congress 2020.Dravet syndrome is a rare, highly refractory form of infant- and childhood-onset epilepsy marked by frequent and often prolonged seizures that are difficult to control with existing medications, significant cognitive and motor impairments, and a higher risk of sudden death.Efficacy was assessed as the reduction in monthly convulsive seizure frequency (MCSF) from core study baseline. Patients experienced a clinically meaningful and statistically significant reduction in MCSF over the entire treatment period of two years (-63%).“In addition to the significant convulsive seizure reductions seen in all three multi-national Phase 3 studies of FINTEPLA in Dravet syndrome, we are proud to collaborate with expert clinician investigators to show the durability of the clinically meaningful seizure reduction that FINTEPLA provided for patients treated for up to two years,” said Bradley S. Galer, Chief Medical Officer at Zogenix.Furthermore, new post-hoc data analysis demonstrated that for every two to three patients treated with Fintepla, one patient achieved ≥75% (profound) convulsive seizure reduction compared with placebo.“We believe these new data analyses further showcase the clinical value that FINTEPLA provides for many Dravet syndrome patients and their families” stated Galer.Shares in ZGNX have plunged over 60% year-to-date, but analysts have a cautiously optimistic Moderate Buy consensus on the stock’s outlook. That’s with an average analyst price target of $45- indicating shares can more than double from current levels.“We continue to believe in Fintepla’s long-term potential to be the standard of care for Dravet Syndrome, particularly following promising early launch indicators” comments Mizuho Securities analyst Difei Yang. She has a buy rating on Zogenix and $55 price target.She sees upside in ZGNX shares driven by Fintepla in Dravet, an area of high unmet medical need and from additional pipeline indications including Lennox–Gastaut syndrome; adding that the firm’s revenue estimates of $4.2mil/$45.7mil for 2020/2021 are achievable with potential upside. (See Zogenix stock analysis on TipRanks)Related News: Vertex Sinks 12% On Halt of VX-814 Development; Merrill Lynch Says Buy J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa More recent articles from Smarter Analyst: * Intuitive Surgical Plunges 4% Despite 3Q Earnings Beat * Cars.com Soars 26% On Strong 3Q Sales Outlook, Analyst Upgrade * Marten Transport Sinks 8% After-Hours On 3Q Revenue Miss * Raytheon Scores $239M US Air Force Contract Modification

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage